Amneal Pharmaceuticals Inc.
Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A. Risk Factors to be a complete statement of all potential risks and uncertainties.
$19.18
-$0.07 (-0.36%)
EOD Oct 16, 2026
13.05% operating margin is respectable but not wide. ROIC at 14.77%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 8.0%, steady but not accelerating.
At 40x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Net debt of $2.41B represents 8.9x FCF, leverage limits flexibility.
40.0x earnings, 47.9x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3.12B
▲ +8.0% YoY
Net Income (TTM)
$157M
▲ +161.6% YoY
Op. Margin
14.56%
▲ +4.1pp YoY
ROIC
13.74%
▲ +5.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$128M
▲ +11.0% YoY
Op. Cash Flow (TTM)
$201M
▲ +15.2% YoY
Net Debt
$2.44B
Cash & Equiv.
$128M
5Y CAGR: +8.7%
5Y CAGR: -3.5%
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 28 Sept 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Amneal Pharmaceuticals (AMRX) overvalued?
At a P/E of 40.0 and a price-to-free-cash-flow of 47.9, Amneal Pharmaceuticals (AMRX) trades above a two-stage DCF intrinsic value of about $-0.69 per share, so at $19.18 the stock looks overvalued (103.6% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Amneal Pharmaceuticals scores 57/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Amneal Pharmaceuticals's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $-0.69 per share for AMRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $-0.52. At today's $19.18, that puts the stock about 103.6% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Amneal Pharmaceuticals a high-quality business?+
Amneal Pharmaceuticals scores 57 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 14.6% operating margin and a 13.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Amneal Pharmaceuticals a good stock to buy right now?+
That depends on valuation and quality together, not either alone. AMRX currently trades above its estimated intrinsic value and scores 57/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.